Imipenem-cilastatin use in a university hospital in Chile;Cumplimiento sobre las recomendaciones de uso y evaluación del impacto económico de un programa de uso restringido de imipenem-cilastatina

Revista Chilena de Infectologia

Volumn 23, Issue 4, 2006, Pages

  Alberto Fica, C ^a   Mario Luppi, M ^b   Roberto Olivares, C ^b   Lorena Brito, F ^c   Isabel Zilleruelo, L ^d   Lorena Munoz C ^d  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^b Sección de Infectología

^c Servicio de Farmacia Hospital Universitari Arnau de Vilanova   (Spain)

^d Unidad de Medicamentos

Author keywords

Active surveillance; Antibiotic restriction policy; Economical impact; Imipenem

Indexed keywords

EID: 33845482500     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. García Moreno J, Dillon J R, Arroyave R, Maldonado A, Fich F, Salvo A, et al. Identification of penicillinase producing Neisseria gonorrhoeae in Chile during clinical and microbiological study of gonococcal susceptibility to antimicrobial agents. Genitourin Med 1987; 63: 6-12.
2. Wolff M. Cambios epidemiológicos en las enfermedades infecciosas del país. Rev Méd Chile 2002; 130: 353-62.
3. Prado V, Pidal P, Arellano C, Lagos R, San Martín O, Levine M. Multirresistencia antimicrobiana en cepas de Shigella sp en una comuna semi rural del área norte de Santiago. Rev Méd Chile 1998; 126: 1464-71.
4. Trucco O, Prado V, Durán C. Red de vigilancia de resistencia antimicrobiana PRONARES: informe primer semestre 2001. Rev Chil Infect 2002; 19 (supl 2): S140-8.
5. Fica A, Díaz P, López M, Zamorano J, Leiva A, Villalobos C. Altos niveles de resistencia en Escherichia coli causante de infecciones urinarias en una comunidad rural del área metropolitana. Rev Chil Infect 1999; 16: 120-6.
6. Fica A, Pino A, Ramírez P, Brunel V, Triantafilo V. Susceptibilidad ante diferentes antimicrobianos en aislamientos de Escherichia coli de infecciones urinarias ambulatorias en Santiago. Revista Hosp Clínico Universidad de Chile 1998; 9: 232-7.
7. Bello H, González G, Domínguez M, Valenzuela L, Zemelman C, Mella S, et al. Detection of extended-spectrum beta-lactamases produced by Chilean isolates of Klebsiella pneumonias by two synergy methods. J Chemother 2004; 16: 312-4.
8. Zemelman C, Bello H, Domínguez M, González G, Mella S, Zemelman R. Activity of cefepime, cefotaxime, ceftazidime, and aztreonam against extended-spectrum-producing isolates of Klebsiella pneumoniae and Escherichia coli from Chilean hospitals. Diagn Microbiol Infect Dis 2001; 40: 41-3.
9. Marovac J, Campos MI. Enterococcus faecium resistente a vancomicina. Rev Méd Chile 2000; 128: 685-6.
10. Vlahovic-Palcevski V, Morovic M, Palcevski G. Antibiotic utilization at the university hospital after introducing an antibiotic policy. Eur J Clin Pharmacol 2000; 56: 97-101.
11. Wilton P, Smith R, Coast J, Millar M. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness. J Health Serv Res Policy 2002; 7: 111-7.
12. Erbay A, Colpan A, Bodur H, Cevik M A, Samore M H, Ergonul O. Evaluation of antibiotic use in a hospital with an antibiotic restriction policy. Int J Antimicrob Agents 2003; 21: 308-12.
13. Keuleyan E, Gould I M. Key issues in developing antibiotic policies: from an institutional level to Europe-wide. European Study Group on Antibiotic Policy (ESGAP), subgroup III. Clin Microbiol Infect 2001; 7 (suppl 6): 16-21.
14. Levin A S, Barone A A, Penco J, Santos M V, Marinho I S, Arruda E A G, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-11.
15. Fica A, Luppi M, Brito L, Castro A, Abusada IN. Impacto de un programa de supervisión sobre el uso de vancomicina en un hospital universitario. Libro de Resúmenes XVIII Congreso Chilene de Infectología, 23 al 26 de agosto del 2001, Pucón. Resumen CO8, pág 91.
16. Sáez-Llorens X, Castrejón-De Wong M, Castaño E, De Suman O, Morós D, De Atencio I. Impact of an antibiotic restriction policy on hospital expenditures and bacterial susceptibilities: a lesson from a pediatric institution in a developing country. Pediatr Infect Dis J 2000; 19: 200-6.
17. Rahal J J, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: 1233-7.
18. Himmelberg C J, Pleasants R A, Weber D J, Kessler J M, Samsa G P, Spivey J M, et al. Use of antimicrobial drugs in adults before and after removal of a restriction policy. Am J Hosp Pharm 1991; 48: 1220-7.